PDCD1 and colorectal carcinoma: For instance, in a phase Ib clinical trial, the combination of a PD-1 inhibitor and the anti-angiogenic agent regorafenib achieved an objective response rate (ORR) of 33% in MSS CRC patients, demonstrating the potential of synergistic therapeutic approaches6.